Sotatercept for treating pulmonary arterial hypertension [ID6163]

Suggested remit: To appraise the clinical and cost effectiveness of sotatercept within its marketing authorisation for treating pulmonary arterial hypertension.

Status:

In progress

Technology type:

Medicine

Decision:

Selected

Reason for decision:

Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources

Process:

STA Standard

ID number:

6163

Project Team

Project lead

Jeremy Powell

Email enquiries

If you have any queries please email TATeam2@nice.org.uk

External Assessment Group:

Health Economics Research Unit and Health Services Research Unit, University of Aberdeen

Stakeholders

Companies sponsors

Merck Sharp & Dohme (sotatercept)

Others

Department of Health and Social Care

 

NHS England

Patient carer groups

Pulmonary Hypertension Association UK

Professional groups

Royal College of Pathologists

 

Royal College of Physicians

 

UK Clinical Pharmacy Association

Associated public health groups

Public Health Wales

 

UK Health Security Agency

Comparator companies

ADVANZ Pharma (epoprostenol) (not participating)

 

Amarox (sildenafil) (not participating)

 

AOP Orphan (treprostinil)

 

Aspire Pharma (tadalafil) (not participating)

 

Aurobindo Pharma (bosentan, sildenafil, tadalafil) (not participating)

 

Bayer (iloprost)

 

Chiesi

 

Cipla EU (ambrisentan, bosentan, tadalafil) (not participating)

 

Colonis Pharma (iloprost) (not participating)

 

Crescent Pharma (sildenafil) (not participating)

 

Dr. Reddy’s Laboratories (ambrisentan, (not participating)

 

bosentan, sildenafil, treprostinil) (not participating)

 

Eli Lilly and Company (tadalafil) (not participating)

 

GlaxoSmithKline (ambrisentan, epoprostenol)

 

Janssen-Cilag (macitentan, epoprostenol, selexipag)

 

Merck Sharp & Dohme (riociguat) (not participating)

 

Mylan (ambrisentan, bosentan, sildenafil, tadalafil) (not participating)

 

Ranbaxy (tadalafil, epoprostenol) (not participating)

 

Rosemont Pharmaceutical (bumetanide, sildenafil) (not participating)

 

Sandoz (sildenafil) (not participating)

 

Sanofi (tadalafil) (not participating)

 

Sigma Pharmaceuticals (sildenafil) (not participating)

 

Sovereign Medical (tadalafil) (not participating)

 

Teva Pharma (sildenafil) (not participating)

 

The Boots Company (sildenafil) (not participating)

 

Tillomed Laboratories (treprostinil) (not participating)

 

Upjohn UK (sildenafil) (not participating)

 

Zentiva (ambrisentan) (not participating)

General commentators

All Wales Therapeutics and Toxicology Centre

 

British National Formulary

 

Department of Health - Northern Ireland

 

Healthcare Improvement Scotland

 

Health Technology Wales

 

Medicines and Healthcare products Regulatory Agency

 

Scottish Medicines Consortium

 

Welsh Government

 

Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

For further information on our processes and methods, please see our CHTE processes and methods manual